Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125038632 | 12503863 | 2 | F | 200702 | 20160702 | 20160628 | 20160713 | EXP | PT-PFIZER INC-2016308940 | PFIZER | 45.00 | YR | F | Y | 0.00000 | 20160713 | MD | PT | PT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125038632 | 12503863 | 1 | PS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Oral | 50 MG, CYCLIC (DAILY, 4 WEEKS ON / 2 WEEKS OF ) | Y | 21938 | 50 | MG | |||||||
| 125038632 | 12503863 | 2 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Oral | 37.5 MG, CYCLIC (DAILY, 4 WEEKS ON / 2 WEEKS OF ) | Y | 21938 | 37.5 | MG | |||||||
| 125038632 | 12503863 | 3 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Oral | 37.5 MG, CYCLIC (DAILY, 4 WEEKS ON / 2 WEEKS OF ) | Y | 21938 | 37.5 | MG | |||||||
| 125038632 | 12503863 | 4 | C | EUTIROX | LEVOTHYROXINE SODIUM | 1 | 175 UG, UNK | 0 | 175 | UG | |||||||||
| 125038632 | 12503863 | 5 | C | EUTIROX | LEVOTHYROXINE SODIUM | 1 | 150 UG, UNK | 0 | 150 | UG | |||||||||
| 125038632 | 12503863 | 6 | C | MALTOFER | IRON POLYMALTOSE | 1 | 375 MG / 5 ML | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125038632 | 12503863 | 1 | Clear cell renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125038632 | 12503863 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125038632 | 12503863 | Anaemia | |
| 125038632 | 12503863 | Asthenia | |
| 125038632 | 12503863 | Clear cell renal cell carcinoma | |
| 125038632 | 12503863 | Constipation | |
| 125038632 | 12503863 | Diarrhoea | |
| 125038632 | 12503863 | Disease progression | |
| 125038632 | 12503863 | Ejection fraction decreased | |
| 125038632 | 12503863 | Gastrointestinal disorder | |
| 125038632 | 12503863 | Hypothyroidism | |
| 125038632 | 12503863 | Intestinal perforation | |
| 125038632 | 12503863 | Nausea | |
| 125038632 | 12503863 | Neutropenia | |
| 125038632 | 12503863 | Normochromic normocytic anaemia | |
| 125038632 | 12503863 | Skin ulcer |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125038632 | 12503863 | 1 | 200701 | 200901 | 0 | |
| 125038632 | 12503863 | 2 | 201106 | 201401 | 0 | |
| 125038632 | 12503863 | 3 | 201403 | 201404 | 0 |